Basal cell carcinoma (BCC) of the prostate, a rare variant of prostate cancer, is derived from the basal cells of prostatic ducts and acini. BCC generally occurs in elderly men with obstructive voiding symptoms and levels of serum prostate-specific antigen within the normal range. In most cases, diagnosis is made through transurethral resection or simple enucleation. Most cases are indolent, but local recurrence and metastasis have been reported in a few cases. Thus, radical surgery and long-term follow-up are recommended. We report a case of a 54-year-old man who underwent radical retropubic prostatectomy after being diagnosed with BCC during a transurethral resection performed for lower urinary tract symptoms. The patient has remained free of disease for 4 months after surgery. We report the case of a patient in whom BCC was diagnosed during transurethral resection for intractable LUTS after 6.5 years of medical treatment for benign prostatic hyperplasia (BPH) and who ultimately underwent radical retropubic prostatectomy.
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Basal cell carcinoma (BCC) of the prostate is a rare variant, comprising ＜0.01% of all malignant tumors of the prostate.
It is derived from the basal cells of the prostatic ducts and acini, and mainly arises from the transition zone. 1, 2 Patients with BCC of the prostate are generally older males with lower urinary tract symptoms (LUTS). In most cases, the diagnosis is made during transurethral resection or simple enucleation of the prostate, because the serum prostate-specific antigen (PSA) level is usually normal. [1] [2] [3] [4] Since BCC of the prostate was first reported in 1974 as adenoid cystic carcinoma (ACC), a part of the morphologic continuum of BCC, 2 approximately 50 cases have been reported worldwide. 2 However, just one case has been reported in the domestic literature. 5 We report the case of a patient in whom BCC was diagnosed during transurethral resection for intractable LUTS after 6.5 years of medical treatment for benign prostatic hyperplasia (BPH) and who ultimately underwent radical retropubic prostatectomy.
CASE REPORT
A 54-year-old male patient visited the outpatient department for LUTS 7 years ago. He had no remarkable past medical history or familial medical history. On digital rectal examination (DRE), the prostate was found to be enlarged (50 ml)
with an indurated and slightly firm consistency without tenderness. The International Prostate Symptom Score and quality of life score were 28 and 5, respectively, and the peak urinary flow rate was 8 ml/s. Urinalysis was normal, but the expressed prostatic secretion revealed many white blood cells per high power field. The serum PSA was 3.5 ng/ml and the prostate volume measured with transrectal ultrasonography was 50 ml. With the clinical impression of chronic prostatitis and BPH, an antibiotic was administered for 2 months and an α-blocker was started and used continuously.
Two years later, his PSA and prostate volume increased to 9.0 ng/ml and 60 ml, respectively. Sextant biopsy of the prostate was performed with the pathologic diagnosis of chronic prostatitis. Subsequently, PSA was followed up periodically, and ranged from 3.8 to 7.5 ng/ml. At 6 years from his first Microscopic examination revealed an ill-defined BCC confined to the prostate along with multifocal prostatic intraepithelial neoplasia (Fig. 3) . No metastasis was found in 22 bilateral obturator and external iliac lymph nodes.
At 4 months after surgery, the patient appeared to be free of cancer with a PSA level of 0.009 ng/ml. Because the PSA level is generally normal or only slightly elevated in patients with BCC, long-term follow-up should include radiographic 
